학술논문

A novel small molecule chaperone of rod opsin and its potential therapy for retinal degeneration.
Document Type
article
Source
Nature Communications. 9(1)
Subject
ATP-Binding Cassette Transporters
Alcohol Oxidoreductases
Animals
Cell Line
Tumor
Disease Models
Animal
Diterpenes
Female
HEK293 Cells
High-Throughput Screening Assays
Humans
Light
Male
Mice
Mice
Inbred C57BL
Mice
Knockout
Mutation
NIH 3T3 Cells
Neuroprotective Agents
Protein Folding
Protein Transport
Retinal Degeneration
Retinal Rod Photoreceptor Cells
Retinaldehyde
Rhodopsin
Thiophenes
Treatment Outcome
Language
Abstract
Rhodopsin homeostasis is tightly coupled to rod photoreceptor cell survival and vision. Mutations resulting in the misfolding of rhodopsin can lead to autosomal dominant retinitis pigmentosa (adRP), a progressive retinal degeneration that currently is untreatable. Using a cell-based high-throughput screen (HTS) to identify small molecules that can stabilize the P23H-opsin mutant, which causes most cases of adRP, we identified a novel pharmacological chaperone of rod photoreceptor opsin, YC-001. As a non-retinoid molecule, YC-001 demonstrates micromolar potency and efficacy greater than 9-cis-retinal with lower cytotoxicity. YC-001 binds to bovine rod opsin with an EC50 similar to 9-cis-retinal. The chaperone activity of YC-001 is evidenced by its ability to rescue the transport of multiple rod opsin mutants in mammalian cells. YC-001 is also an inverse agonist that non-competitively antagonizes rod opsin signaling. Significantly, a single dose of YC-001 protects Abca4 -/- Rdh8 -/- mice from bright light-induced retinal degeneration, suggesting its broad therapeutic potential.